High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma
In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1988-12, Vol.58 (6), p.779-782 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 782 |
|---|---|
| container_issue | 6 |
| container_start_page | 779 |
| container_title | British journal of cancer |
| container_volume | 58 |
| creator | MBIDDE, E. K SELBY, P. J PERREN, T. J DEARNALEY, D. P WHITTON, A ASHLEY, S WORKMAN, P BLOOM, H. J. G MCELWAIN, T. J |
| description | In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national studies, there appeared to be a small prolongation of survival but no increase in the proportion of long survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return. Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified. |
| doi_str_mv | 10.1038/bjc.1988.308 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2246887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2852028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-b798a241960823125927718759edda58e72494c9bc3fac4784e59396627741633</originalsourceid><addsrcrecordid>eNpVkc1rGzEQxUVpSBy3t14DOvTYdfS1K-lSaE0SB0J7aXoVs1qtd8N6ZSRtjMk_Hxkb057E6L35STMPoS-ULCjh6rZ-sQuqlVpwoj6gGS05K6hi8iOaEUJkQTQjV-g6xpdcaqLkJbpkqmSEqRl6W_XrDjc-Ovxz-esZ285tfOpcgO0e7_rUYZiSH_zaTxHXfnR4AyH4HU4BxrgdYEyQej9iGBvcTsNwZAVo-jOm9QGv843Dj38xxBS83Se_gU_oooUhus-nc46e7-_-LFfF0--Hx-WPp8IKolJRS62ACaorohinrNRMSqpkqV3TQKmcZEILq2vLW7BCKuFKzXVVZZugFedz9P3I3U71xjXWjfnzg9mGPs-yNx56878y9p1Z-1fDmKiUkhnw7QiwwccYXHvupcQcMjA5A3PIwOQMsv3m3_fO5tPSs_71pEO0MLR5k7aPZ9thNsEZfwfSaZE5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>MBIDDE, E. K ; SELBY, P. J ; PERREN, T. J ; DEARNALEY, D. P ; WHITTON, A ; ASHLEY, S ; WORKMAN, P ; BLOOM, H. J. G ; MCELWAIN, T. J</creator><creatorcontrib>MBIDDE, E. K ; SELBY, P. J ; PERREN, T. J ; DEARNALEY, D. P ; WHITTON, A ; ASHLEY, S ; WORKMAN, P ; BLOOM, H. J. G ; MCELWAIN, T. J</creatorcontrib><description>In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national studies, there appeared to be a small prolongation of survival but no increase in the proportion of long survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return. Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1988.308</identifier><identifier>PMID: 2852028</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adult ; Antineoplastic agents ; Biological and medical sciences ; Bone Marrow - drug effects ; Bone Marrow Transplantation ; Brain Neoplasms - drug therapy ; Brain Neoplasms - radiotherapy ; Brain Neoplasms - therapy ; Carmustine - adverse effects ; Carmustine - pharmacokinetics ; Carmustine - therapeutic use ; Chemotherapy ; Combined Modality Therapy ; Female ; Glioblastoma - drug therapy ; Glioblastoma - radiotherapy ; Glioblastoma - therapy ; Humans ; Leukopenia - chemically induced ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Thrombocytopenia - chemically induced ; Time Factors</subject><ispartof>British journal of cancer, 1988-12, Vol.58 (6), p.779-782</ispartof><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-b798a241960823125927718759edda58e72494c9bc3fac4784e59396627741633</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246887/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246887/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7187432$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2852028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MBIDDE, E. K</creatorcontrib><creatorcontrib>SELBY, P. J</creatorcontrib><creatorcontrib>PERREN, T. J</creatorcontrib><creatorcontrib>DEARNALEY, D. P</creatorcontrib><creatorcontrib>WHITTON, A</creatorcontrib><creatorcontrib>ASHLEY, S</creatorcontrib><creatorcontrib>WORKMAN, P</creatorcontrib><creatorcontrib>BLOOM, H. J. G</creatorcontrib><creatorcontrib>MCELWAIN, T. J</creatorcontrib><title>High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national studies, there appeared to be a small prolongation of survival but no increase in the proportion of long survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return. Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified.</description><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow - drug effects</subject><subject>Bone Marrow Transplantation</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Brain Neoplasms - therapy</subject><subject>Carmustine - adverse effects</subject><subject>Carmustine - pharmacokinetics</subject><subject>Carmustine - therapeutic use</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - radiotherapy</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Leukopenia - chemically induced</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Thrombocytopenia - chemically induced</subject><subject>Time Factors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1rGzEQxUVpSBy3t14DOvTYdfS1K-lSaE0SB0J7aXoVs1qtd8N6ZSRtjMk_Hxkb057E6L35STMPoS-ULCjh6rZ-sQuqlVpwoj6gGS05K6hi8iOaEUJkQTQjV-g6xpdcaqLkJbpkqmSEqRl6W_XrDjc-Ovxz-esZ285tfOpcgO0e7_rUYZiSH_zaTxHXfnR4AyH4HU4BxrgdYEyQej9iGBvcTsNwZAVo-jOm9QGv843Dj38xxBS83Se_gU_oooUhus-nc46e7-_-LFfF0--Hx-WPp8IKolJRS62ACaorohinrNRMSqpkqV3TQKmcZEILq2vLW7BCKuFKzXVVZZugFedz9P3I3U71xjXWjfnzg9mGPs-yNx56878y9p1Z-1fDmKiUkhnw7QiwwccYXHvupcQcMjA5A3PIwOQMsv3m3_fO5tPSs_71pEO0MLR5k7aPZ9thNsEZfwfSaZE5</recordid><startdate>19881201</startdate><enddate>19881201</enddate><creator>MBIDDE, E. K</creator><creator>SELBY, P. J</creator><creator>PERREN, T. J</creator><creator>DEARNALEY, D. P</creator><creator>WHITTON, A</creator><creator>ASHLEY, S</creator><creator>WORKMAN, P</creator><creator>BLOOM, H. J. G</creator><creator>MCELWAIN, T. J</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19881201</creationdate><title>High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma</title><author>MBIDDE, E. K ; SELBY, P. J ; PERREN, T. J ; DEARNALEY, D. P ; WHITTON, A ; ASHLEY, S ; WORKMAN, P ; BLOOM, H. J. G ; MCELWAIN, T. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-b798a241960823125927718759edda58e72494c9bc3fac4784e59396627741633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow - drug effects</topic><topic>Bone Marrow Transplantation</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Brain Neoplasms - therapy</topic><topic>Carmustine - adverse effects</topic><topic>Carmustine - pharmacokinetics</topic><topic>Carmustine - therapeutic use</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - radiotherapy</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Leukopenia - chemically induced</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Thrombocytopenia - chemically induced</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MBIDDE, E. K</creatorcontrib><creatorcontrib>SELBY, P. J</creatorcontrib><creatorcontrib>PERREN, T. J</creatorcontrib><creatorcontrib>DEARNALEY, D. P</creatorcontrib><creatorcontrib>WHITTON, A</creatorcontrib><creatorcontrib>ASHLEY, S</creatorcontrib><creatorcontrib>WORKMAN, P</creatorcontrib><creatorcontrib>BLOOM, H. J. G</creatorcontrib><creatorcontrib>MCELWAIN, T. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MBIDDE, E. K</au><au>SELBY, P. J</au><au>PERREN, T. J</au><au>DEARNALEY, D. P</au><au>WHITTON, A</au><au>ASHLEY, S</au><au>WORKMAN, P</au><au>BLOOM, H. J. G</au><au>MCELWAIN, T. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>1988-12-01</date><risdate>1988</risdate><volume>58</volume><issue>6</issue><spage>779</spage><epage>782</epage><pages>779-782</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national studies, there appeared to be a small prolongation of survival but no increase in the proportion of long survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return. Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>2852028</pmid><doi>10.1038/bjc.1988.308</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1988-12, Vol.58 (6), p.779-782 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2246887 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Antineoplastic agents Biological and medical sciences Bone Marrow - drug effects Bone Marrow Transplantation Brain Neoplasms - drug therapy Brain Neoplasms - radiotherapy Brain Neoplasms - therapy Carmustine - adverse effects Carmustine - pharmacokinetics Carmustine - therapeutic use Chemotherapy Combined Modality Therapy Female Glioblastoma - drug therapy Glioblastoma - radiotherapy Glioblastoma - therapy Humans Leukopenia - chemically induced Male Medical sciences Middle Aged Pharmacology. Drug treatments Thrombocytopenia - chemically induced Time Factors |
| title | High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A19%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20dose%20BCNU%20chemotherapy%20with%20autologous%20bone%20marrow%20transplantation%20and%20full%20dose%20radiotherapy%20for%20grade%20IV%20astrocytoma&rft.jtitle=British%20journal%20of%20cancer&rft.au=MBIDDE,%20E.%20K&rft.date=1988-12-01&rft.volume=58&rft.issue=6&rft.spage=779&rft.epage=782&rft.pages=779-782&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1988.308&rft_dat=%3Cpubmed_cross%3E2852028%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2852028&rfr_iscdi=true |